These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27346829)

  • 41. Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects.
    Bánvölgyi A; Anker P; Lőrincz K; Kiss N; Márton D; Fésűs L; Gyöngyösi N; Wikonkál N
    J Dermatolog Treat; 2020 Jun; 31(4):387-398. PubMed ID: 31039644
    [No Abstract]   [Full Text] [Related]  

  • 42. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
    Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib.
    Smith SDB; Clarke CN; Clark MA; Harker-Murray AK; Sokumbi O
    Am J Dermatopathol; 2021 Aug; 43(8):585-587. PubMed ID: 33534208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
    Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
    J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities.
    Spallone G; Sollena P; Ventura A; Fargnoli MC; Gutierrez C; Piccerillo A; Tambone S; Bianchi L; Peris K
    Dermatol Ther; 2019 Nov; 32(6):e13108. PubMed ID: 31606940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.
    Fife D; Laitinen MA; Myers DJ; Landsteiner PB
    Pediatr Dermatol; 2017 Mar; 34(2):163-165. PubMed ID: 28297142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 51. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
    Juhasz ML; Marmur ES
    J Drugs Dermatol; 2014 Jun; 13(6):729-33. PubMed ID: 24918565
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
    Fife K; Herd R; Lalondrelle S; Plummer R; Strong A; Jones S; Lear JT
    Future Oncol; 2017 Jan; 13(2):175-184. PubMed ID: 27640448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease].
    Reinders MG; Terra JB; Reyners AK; Aarts MJ; de Haas ER; Mosterd K
    Ned Tijdschr Geneeskd; 2016; 160():D187. PubMed ID: 28000572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
    Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M
    JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
    Ali FR; Lear JT
    Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 57. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
    Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
    Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
    Nayyar PM; Chang ALS; Sarin K; Ratner D
    Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
    [No Abstract]   [Full Text] [Related]  

  • 59. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
    Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
    Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.